Sparc - Abraxis Biosciences has filed a complaint in the U.S. Court which alleges that the Spark's filing of new drug application for Taclantis injection as an act of infringement of the Orange Book listed patents for Abraxane. Sentimentally Negative
Feedback
SPARC 
Reputation: 13,324 • Aug 21, 2019 2:29 PM
Vote
Comment
Share